Shire's Vyvanse wins FDA nod as maintenance for pediatric ADHD

05/3/2013 | Medscape (free registration)

Shire obtained FDA approval to market Vyvanse, or lisdexamfetamine dimesylate, as maintenance therapy for children and teenagers with attention deficit hyperactivity disorder. This makes Vyvanse the only stimulant approved for use as a maintenance therapy in all ADHD patients older than 6, Shire says. The approval was based on data from a 32-week trial that showed lower treatment-failure rate among those who received Vyvanse.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA
Assistant General Counsel, Regulatorya
Cardinal Health
Waukegan, IL
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA